Abstract
Evaluation of immunoprofile as predictive and prognostic biomarker are essential to follow up patients in Multiple Myeloma after autologous hematopoietic stem cells transplantation (AHSCT). It can be defining the engraftment and predicts complications. An AHSCT was performed for the first time in the United Arab Emirates to treat a patient with multiple myeloma. We apply the evaluation of the patient's immune status before and during the early follow-up by flow and mass cytometry. The analysis revealed a decrease in all leukocyte populations in blood seven days after transplantation, mainly of B and T helper lymphocytes. The patients showed diarrhea and cellulitis as complications. An increase in regulatory T and NK lymphocytes was evidenced at the same time. 28 days’ post-transplantation, all lymphocyte populations were recovered, except for B lymphocytes, a high level of T regulatory and NK was maintained. The early immune restoration coincided with the recovery of the complications presented by the patient. the leukocyte composition of apheresis was similar to that found in blood at baseline time. Our study evidenced that the extended immunoprofile by mass cytometry could be useful to predict the outcome and response to transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Hematology & Transfusion International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.